A novel COL3A1 variant associated with vascular Ehlers–Danlos syndrome in a patient presents as recurrent pneumothorax with cavities
Year: 2023
Type: article
Study design: Case Report
Abstract: This article emphasizes the relationship between the COL3A1 gene and vascular Ehlers–Danlos syndrome (EDS), in a 14-year-old patient who was hospitalized due to recurrent chest pain. Imaging studies revealed recurrent pneumothorax and migratory lung nodules, meanwhile, anti-infection therapy was ineffective. The study expands the COL3A1 gene spectrum and provides significant clinical guidance for EDS syndrome with predominantly respiratory symptoms. The Ehlers–Danlos syndromes (EDS) are a group of rare connective disorders characterized by skin hyperextensible, joint hypermobility, and easy bruising.1 Vascular EDS (vEDS; OMIM: 130050) is a subtype of EDS that results from the heterozygous pathogenetic variants within the collagen type III alpha-1 chain (COL3A1) gene.2 The diagnosis of vEDS is established by detecting pathogenic variants in COL3A1, or by biochemical analysis of type III procollagen from cultured fibroblasts in the absence of a pathogenic variant in COL3A1.2 We identified a novel variant in COL3A1, NM_000090.4: c.3275G>A, p.(Gly1092Asp), in a 14-year-old Chinese patient with recurrent pneumothorax. The 14-year-old Chinese patient first came to our hospital with chest pain, coughing, and recurrent hemoptysis. The X-ray showed pneumothorax (Figure 1A), and chest computed tomography (CT) exhibited cavities (Figure 1B and C). Combined with the imaging manifestations and clinical features, the possibility of pulmonary infection could not be ruled out, so the patient was given intravenous mezlocillin anti-infection treatment and assisted with chest drainage. After 10 days of treatment, the patient’s chest pain and hemoptysis symptoms were better than before, but imaging still suggested some cavities and ground-glass nodules. Chest CT showed pneumothorax disappeared, and partial cavities were absorbed while solid nodules were detected (Figure 1E). Meanwhile, ground-glass opacities appeared in the upper lobe of the right lung (Figure 1D). The patient was instructed to take oral sulfamethoxazole outside the hospital. Chest X-ray and High-resolution CT images. (A) Initial chest X-ray showed left pneumothorax. (B) Chest CT showed a cavity in the left lung. (C) Chest CT indicated a cavity in the left lung. (D) Chest CT showed a novel ground glass nodule in the right lung after anti-infection treatment. (E) Chest CT showed progression of cavities to nodules in the left lung after anti-infection treatment. (F) Chest X-ray showed left pneumothorax after 6 months. (G) Chest CT showed cystic fusion in the left lung. (H) Chest CT showed nodules in both lungs. (I) Chest CT showed a novel cavity in the right lung after anti-infection treatment. (J) Chest CT showed nodules disappeared after anti-infection treatment. Six months later, the patient returned to our hospital with sudden chest pain and shortness of breath. Chest X-ray suggested that the patient had pneumothorax again, and chest CT results showed cavities and solid nodules in both lungs in addition to the pneumothorax (Figure 1G and H). Subsequent bronchoscopy was performed on the patient, and no pathogenic bacteria were detected by bacterial culture and metagenomic next-generation sequencing. Anti-bacteria treatments with praziquantel were less effective, including mezlocillin, linezolid, cefoperazone-sulbactam, and anti-parasites treatment with praziquantel. Almost a month after the anti-infection treatment, the chest CT revealed that the pneumothorax had disappeared but that new cavities had developed (Figure 1I and J). To further clarify the cause of the disease, a surgical lung biopsy was performed for pathological analysis, and the pulmonary pathological findings showed hemosiderosis, and fibrous nodule with ossification, indicating a high probability of vEDS (Figure 2A). Next, whole-exome sequencing was performed. After variant filtering, a novel variant NM_000090.4:c.3275G>A, p.(Gly1092Asp) was identified. The variant was confirmed using Sanger sequencing (Figure 2B). According to the ACMG guideline, the novel COL3A1 variant can be classified as likely pathogenic (PM1 + PM2 + PM5 + PP2 + PP3). Pulmonary pathological investigation and Sanger sequencing. (A) The pathological results showed fibrous nodules with ossification, surrounded by deposits of hemosiderosis. (B) Sanger sequencing showed the patient was carrying a novel COL3A1 variant, NM_000090.4:c.3275G>A, p.(Gly1092Asp). vEDS is caused by heterozygous pathogenic variants in COL3A1. COL3A1 is located on chromosome 2, consists of 51 exons, encodes 1466 amino acids, and is responsible for forming type III collagen. Type III collagen is a triple-helix structure in which glycine plays a vital role in forming and stability. Spontaneous pneumothorax can be an early warning sign of vEDS, appearing before intestinal and vascular problems sometimes.3 Only vEDS includes pneumothorax or hemopneumothorax as one of the diagnostic criteria.4 Rupture of pulmonary blebs is probably the major cause of pneumothorax.2 In vEDS, the pulmonary histological manifestations mainly present as hemosiderosis, fibrous nodules with ossification or bone marrow formation, vascular disruption, and emphysematous changes.5 Recent investigations summarized the chest radiography characteristics, which are primarily characterized by emphysema, linear opacities related to the pleura, and cavitating nodules.3 vEDS is the most severe type of EDS because patients often suffer sudden death due to large arterial ruptures.6 We also advised our patient to further evaluate the arteries, but the patient refused. The management of vEDS includes maintaining blood pressure in the normal range, rating hypertension aggressively, and surveillance of vascular tree via Doppler ultrasound, computed tomography angiography or magnetic resonance angiography if feasible on an annual basis. Currently, there are no drugs for treating vEDS. Cicloprolol, a hypertensive drug with both the β1-adrenoceptor blockade and β2-receptor agonism, may help reduce vascular complications and improve prognosis, but further confirmation is needed.7 vEDS involving the lungs alone is rare and challenging to diagnose. When a young patient presents with hemoptysis and pneumothorax, and the pulmonary imaging showed nodules, cavities, or cysts without an obvious inflammatory response, and anti-infection treatment is ineffective, vEDS should be considered. The genetic test is essential for diagnosing vEDS, and regular vessel investigation and follow-up are necessary for proper management. T.G., Y.L. and S.Q.L. collected the data and wrote the manuscript. C.L., H.W., Y.J., D.Y., R.W., B.Y., C.Y.L., X.Y., S.D. and L.W. analyzed, interpreted the data, and performed the clinical assessment. H.L. and H.P. designed the study and performed the clinical assessment. All authors reviewed, edited and approved the final manuscript. The studies involving human participants were reviewed and approved by the Review Board of the Second Xiangya Hospital of Central South University in China. Written informed consent was obtained from the patient for the publication of any potentially identifiable images or data included in this article. This study was supported by National Natural Science Foundation of China (81900002 to T.G., 82070003 to H.L.), Natural Science Foundation of Hunan Province, China (2020JJ5805 to T.G., 2021JJ30943 to H.L.), the Science and Technology Program of Changsha, China (kq1901120 to H.L.), Xiangya Medical Big Data of Central South University (Pulmonary Inflammatory Disease) and the National Key Clinical Specialty Construction Projects of China ((2012) No.650). Conflict of interest: None declared. The authors wish to thank the patient and medical staff of the Department of Pulmonary and Critical Care Medicine for their help and collaborations.
Source: QJM
Language: English
Subfield: Genetics
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4366352671
